What's in European Lung Cancer Working Party's pipeline?

European Lung Cancer Working Party has 6 drugs in our index: 0 marketed, 0 filed, 4 in Phase 3, 2 in Phase 2, 0 in Phase 1.

Which companies overlap with European Lung Cancer Working Party's portfolio?

Top competitors by shared drug class: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Shanghai Junshi Bioscience Co., Ltd..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/european-lung-cancer-working-party.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

European Lung Cancer Working Party — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

European Lung Cancer Working Party pipeline: 0 marketed, 0 filed, 4 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 4 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Cisplatin + etoposide	Cisplatin + etoposide	phase 3	Chemotherapy combination (platinum agent + topoisomerase II inhibitor)	DNA (cisplatin: alkylating agent); Topoisomerase II (etoposide)	Oncology
Cisplatin, Ifosfamide, Gemcitabine	Cisplatin, Ifosfamide, Gemcitabine	phase 3	Combination chemotherapy (platinum agent + alkylating agent + nucleoside analog)		Oncology
Epirubicin + ifosfamide + etoposide	Epirubicin + ifosfamide + etoposide	phase 3	Combination chemotherapy (anthracycline + alkylating agent + topoisomerase II inhibitor)		Oncology
Ifosfamide, Gemcitabine	Ifosfamide, Gemcitabine	phase 3	Chemotherapy combination (alkylating agent + nucleoside analog)		Oncology

Therapeutic area mix

Oncology · 5

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · 1 shared drug class
Shanghai Junshi Bioscience Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for European Lung Cancer Working Party:

Cite this brief

Drug Landscape (2026). European Lung Cancer Working Party — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/european-lung-cancer-working-party. Accessed 2026-05-17.